License and supply agreement with Genuine Health
RNS & Investor News
Appointment of Head of Online Sales and Marketing
19 April 2018
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the appointment of Steven Riley as Head of Online Sales and Marketing. Steven will join the Company on 2 May 2018.
Steven has over eight years' sales and marketing experience within the food, nutrition and nutraceuticals industries. He comes with a wealth of digital marketing experience including website management, social media engagement and online sales platforms. Steven has a degree in marketing and experience in "B2B" sales and will lead the development of the OptiBiotix online presence as another revenue generating business in its own right.
OptiBiotix will use the online platform as a display window to attract potential partners, as they have done with GoFigure®, which led to a deal with Tata Chemical for SlimBiome®. Through this platform, the Company hopes to reach a larger audience by further extending their range with health promoting products, and to continue to develop products which help and support an active and healthy lifestyle. The Company will extend its offering online with the CholBiome® range that should enable it to attract further partners for LPLDL® such as Trigen Pharma as announced on 18 April 2018.
Per Rehné, Commercial Director of OptiBiotix, commented: "Steven's digital marketing and B2B sales experience in the food ingredient, sports nutrition and food industry fields will speed up the process of developing our OptiBiotix online presence. We want to develop this as display window to attract B2B partners and major retailers. This creates another channel for OptiBiotix that will generate revenues from OptiBiotix's growing pipeline of products and we believe it has the potential to grow into a business in its own right."
For further information, please contact:
|OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
|Walbrook PR Ltd
|Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020